A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Vaishalee Kenkre, MD
University of Wisconsin, Madison
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Northwestern University
Chicago, Illinois, United States
- University of Illinois Cancer Center
Chicago, Illinois, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Jan 2023
- Primary completion
- 31 May 2026
- Completion
- 31 May 2027
- Last update posted
- 17 Feb 2026
- Registered enrollment
- 42
- Registry id
- NCT05551936
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.